PE20050596A1 - Microemulsion que comprende un inhibidor renina - Google Patents

Microemulsion que comprende un inhibidor renina

Info

Publication number
PE20050596A1
PE20050596A1 PE2004001233A PE2004001233A PE20050596A1 PE 20050596 A1 PE20050596 A1 PE 20050596A1 PE 2004001233 A PE2004001233 A PE 2004001233A PE 2004001233 A PE2004001233 A PE 2004001233A PE 20050596 A1 PE20050596 A1 PE 20050596A1
Authority
PE
Peru
Prior art keywords
alkyl
hydroxy
amino
hydrogenated
amide
Prior art date
Application number
PE2004001233A
Other languages
English (en)
Inventor
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050596A1 publication Critical patent/PE20050596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA ADMINISTRACION ORAL, LA CUAL COMPRENDE UNA AMIDA DEL ACIDO õ-AMINO-Y-HIDROXI-W-ARIL-ALCANOICO EN UN MEDIO PORTADOR MEJORADO DE ABSORCION QUE COMPRENDE: a) UN COMPONENTE LIPOFILICO SELECCIONADO DE UN TENSOACTIVO DE BAJO EQUILIBRIO HIDROFILICO-LIPOFILICO BASADO EN UN ACIDO GRASO DE CADENA MEDIANA O UNA MEZCLA DE ACIDOS GRASOS DE LA MISMA Y UN ACEITE O MEZCLA DE TRIGLICERIDOS; b) UN TENSOACTIVO DE ALTO EQUILIBRIO HIDROFILICO-LIPOFILICO SELECCIONADO DEPOLISORBATO 80, HIDROXIESTEARATO DE MACROGOL-15, VITAMINA E-TPGS Y ACEITE DE RICINO HIDROGENADO DE POLIOXILO 40 Y c) UN COMPONENTE HIDROFILICO CUYA COMPOSICION AL MEZCLARSE FORMAN UN PRECONCENTRADO EN MICROEMULSION ESTABLE. EL INHIBIDOR DE RENINA DE AMIDA DEL ACIDO õ-AMINO-Y-HIDROXI-W-ARIL-ALCANOICO TIENE LA FORMULA I DONDE R1 ES ALCOXILO C1-C4, ALQUILO C1-C4; R2 ES ALQUILO C1-C4, ALCOXILO C1-C4; R3 Y R4 SON ALQUILO C3-C4, ENTRE OTROS. UN INHIBIDOR DE RENINA PREFERIDO ES HEMIFUMARATO DE (2-CARBAMOIL-2-METIL-PROPIL)-AMIDA DEL ACIDO (2S,4S,5S,7S)-5-AMINO-4-HIDROXI-2-ISOPROPIL-7-[4-METOXI-3-(3-METOXI-PROPOXI)-BENCIL]-8-METIL-NONANOICO
PE2004001233A 2003-12-19 2004-12-10 Microemulsion que comprende un inhibidor renina PE20050596A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156203P 2003-12-19 2003-12-19
US54767604P 2004-02-25 2004-02-25

Publications (1)

Publication Number Publication Date
PE20050596A1 true PE20050596A1 (es) 2005-10-18

Family

ID=34704303

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001233A PE20050596A1 (es) 2003-12-19 2004-12-10 Microemulsion que comprende un inhibidor renina

Country Status (14)

Country Link
US (2) US20070082016A1 (es)
EP (1) EP1729748A1 (es)
JP (2) JP2007514697A (es)
KR (1) KR20060130072A (es)
CN (1) CN1893932B (es)
AR (1) AR047287A1 (es)
AU (1) AU2004298758B2 (es)
BR (1) BRPI0417535A (es)
CA (1) CA2547195A1 (es)
MX (1) MXPA06006926A (es)
PE (1) PE20050596A1 (es)
RU (1) RU2006125742A (es)
TW (1) TW200526200A (es)
WO (1) WO2005058291A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580862A1 (en) * 2004-10-08 2006-04-20 Novartis Ag Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
ATE415944T1 (de) * 2005-07-08 2008-12-15 Physica Pharma Klare pharmazeutische wässrige mikroemulsion mit propofol und herstellungsverfahren
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
NZ591261A (en) * 2008-09-12 2012-12-21 Critical Pharmaceuticals Ltd Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
KR20120105465A (ko) * 2009-11-09 2012-09-25 캡슈겔 벨지엄 엔브이 송달용 담체
TW201136582A (en) * 2010-03-16 2011-11-01 Novartis Ag Improved pharmaceutical compositions of aliskiren and methods of delivery
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN114366808B (zh) * 2021-12-14 2023-10-13 南京农业大学 一种多糖和病毒抗原共递送纳米疫苗、其制备方法及应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
ES2136620T3 (es) * 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
WO1994023749A1 (en) * 1993-04-19 1994-10-27 Institute For Advanced Skin Research Inc. Microemulsion preparation containing difficultly absorbable substance
DE69535127T2 (de) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. Emulgierte arzneistoffabgabesysteme
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
DE19548013A1 (de) * 1995-12-21 1997-06-26 Beiersdorf Ag Verfahren zur Herstellung von O/W- oder O/W/O-Emulsionen sowie nach solchen Verfahren erhältliche O/W- und O/W/O-Emulsionen
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
ZA97457B (en) * 1997-01-20 1997-10-29 Astra Ab Microemulsions for use as vehicles for administration of active compounds.
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
DE19814739A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verwendung von Polyalkylenoxid-haltigen Pfropfpolymerisaten als Solubilisatoren
FR2787026B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
AU2001280135A1 (en) * 2000-08-25 2002-03-04 Takeda Chemical Industries Ltd. Fibrinogen lowering agents
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin

Also Published As

Publication number Publication date
AR047287A1 (es) 2006-01-11
EP1729748A1 (en) 2006-12-13
CN1893932A (zh) 2007-01-10
US20080146671A1 (en) 2008-06-19
BRPI0417535A (pt) 2007-03-27
MXPA06006926A (es) 2006-08-23
AU2004298758B2 (en) 2008-08-07
WO2005058291A1 (en) 2005-06-30
JP2007514697A (ja) 2007-06-07
RU2006125742A (ru) 2008-01-27
AU2004298758A1 (en) 2005-06-30
KR20060130072A (ko) 2006-12-18
TW200526200A (en) 2005-08-16
CN1893932B (zh) 2010-05-26
JP2012067133A (ja) 2012-04-05
CA2547195A1 (en) 2005-06-30
US20070082016A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
PE20050596A1 (es) Microemulsion que comprende un inhibidor renina
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
ES2174462T3 (es) Formulacion autoestimulante para compuestos lipofilos.
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
ATE339408T1 (de) Terphenylderivate, deren herstellung und zusammensetzungen, die diese enthalten
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR048891A2 (es) Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv
ES2523873T3 (es) Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
AR069789A1 (es) Pirazoles condensados, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento del sida o el arc.
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
AR032586A1 (es) Composicion farmaceutica
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
AR046874A1 (es) Nuevos metodos
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN
EA200601373A1 (ru) Нитрат бутоконазола высокой степени чистоты с частицами заданного размера и способ его получения
CL2004000512A1 (es) Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes
HUP0302970A2 (hu) Aminosavak felhasználása fájdalom kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200900068A1 (ru) Способ получения формы i кандесартана цилексетила

Legal Events

Date Code Title Description
FC Refusal